Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1969 May;48(5):940–946. doi: 10.1172/JCI106053

Factor XIII in human plasma and platelets

Jan McDonagh 1,2,3, R P McDonagh Jr 1,2,3, J-M Delâge 1,2,3, Robert H Wagner 1,2,3
PMCID: PMC322303  PMID: 5780202

Abstract

Plasma and platelet factor XIII levels were measured in normal human donors and in a patient congenitally deficient in factor XIII. The purpose of these experiments was to study the role of platelet factor XIII in blood coagulation. On polyacrylamide disc electrophoresis, factor XIII activity in extracts of washed normal platelets appeared as a single peak. This peak was missing or very low when factor XIII-deficient platelet extract was used. The patient was also studied before and after transfusion of fresh frozen plasma. Before transfusion, factor XIII activity could not be detected in the patient's plasma or platelet extracts. 24 hr after transfusion the plasma factor XIII level was still at the anticipated value, but factor XIII activity could not be detected in the platelet extracts. These experiments imply that plasma factor XIII was not transported across the platelet membrane in measurable quantities in vivo. This suggests that platelet factor XIII is a true platelet component and originates in the platelet precursor, the megakaryocyte. Thrombelastographic studies suggest that platelet factor XIII participates in the coagulation process. Thrombelastograms of factor XIII-deficient samples had decreased maximum amplitude and clot elasticity values. The abnormalities were fully corrected by the addition of washed normal platelets to factor XIII-deficient plasma; preincubation of the normal platelets in the deficient plasma had no additional effect. This indicates that platelet factor XIII is immediately available during clot formation.

Full text

PDF
941

Images in this article

942Image
on p.942
943Image
on p.943

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARRY A., DELAGE J. M. CONGENITAL DEFICIENCY OF FIBRIN-STABILIZING FACTOR. OBSERVATION OF A NEW CASE. N Engl J Med. 1965 May 6;272:943–947. doi: 10.1056/NEJM196505062721804. [DOI] [PubMed] [Google Scholar]
  2. BRINKHOUS K. M., LEROY E. C., CORNELL W. P., BROWN R. C., HAZLEHURST J. L., VENNART G. P. Macroscopic studies of platelet agglutination; nature of thrombocyte agglutinating activity of plasma. Proc Soc Exp Biol Med. 1958 Jun;98(2):379–383. doi: 10.3181/00379727-98-24050. [DOI] [PubMed] [Google Scholar]
  3. Britten A. F. Congenital deficiency of factor 13 (fibrin-stabilizing factor): Report of a case and review of the literature. Am J Med. 1967 Nov;43(5):751–761. doi: 10.1016/0002-9343(67)90117-9. [DOI] [PubMed] [Google Scholar]
  4. Bucher U., Kummer H. Die praktische Durchführung der Blutplättchentransfusion. Schweiz Med Wochenschr. 1968 Oct 19;98(42):1635–1641. [PubMed] [Google Scholar]
  5. DAVIS B. J. DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS. Ann N Y Acad Sci. 1964 Dec 28;121:404–427. doi: 10.1111/j.1749-6632.1964.tb14213.x. [DOI] [PubMed] [Google Scholar]
  6. DUCKERT F., JUNG E., SHMERLING D. H. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh. 1960 Dec 15;5:179–186. [PubMed] [Google Scholar]
  7. Egeblad K., Astrup T. Effects of human plasma on thrombelastographic patterns produced by fibrinolytic agents in fibrin clots. Br J Haematol. 1967 Jan;13(1):10–13. doi: 10.1111/j.1365-2141.1967.tb08690.x. [DOI] [PubMed] [Google Scholar]
  8. Fisher S. Fibrinase deficiency. Isr J Med Sci. 1965 Jul;1(4):855–856. [PubMed] [Google Scholar]
  9. HARTERT H. Die Thrombelastographie, eine Methode zur physikalischen Analyse des Blutgerinnungsvorganges. Z Gesamte Exp Med. 1951;117(2):189–203. [PubMed] [Google Scholar]
  10. IKKALA E., MYLLYLAE G., NEVANLINNA H. R. TRANSFUSION THERAPY IN FACTOR 13 (F.S.F.) DEFICIENCY. Scand J Haematol. 1964;1:308–312. doi: 10.1111/j.1600-0609.1964.tb00028.x. [DOI] [PubMed] [Google Scholar]
  11. Kiesselbach T. H., Wagner R. H. Fibrin-stabilizing factor: a thrombin-labile platelet protein. Am J Physiol. 1966 Dec;211(6):1472–1476. doi: 10.1152/ajplegacy.1966.211.6.1472. [DOI] [PubMed] [Google Scholar]
  12. Kiesselbach T. H., Wagner R. H. Platelet and plasma Factor 13 (fibrin-stabilizing factor). Thromb Diath Haemorrh Suppl. 1967;26:155–165. [PubMed] [Google Scholar]
  13. LORAND L., KONISHI K. ACTIVATION OF THE FIBRIN STABILIZING FACTOR OF PLASMA BY THROMBIN. Arch Biochem Biophys. 1964 Apr;105:58–67. doi: 10.1016/0003-9861(64)90235-8. [DOI] [PubMed] [Google Scholar]
  14. LOSOWSKY M. S., HALL R., GOLDIE W. CONGENITAL DEFICIENCY OF FIBRIN-STABILISING FACTOR; A REPORT OF THREE UNRELATED CASES. Lancet. 1965 Jul 24;2(7404):156–158. doi: 10.1016/s0140-6736(65)90233-3. [DOI] [PubMed] [Google Scholar]
  15. LUSCHER E. F. Ein fibrinstabilisierender Faktor aus Thrombocyten. Schweiz Med Wochenschr. 1957 Oct 2;87(39-40):1220–1221. [PubMed] [Google Scholar]
  16. Lorand L., Downey J., Gotoh T., Jacobsen A., Tokura S. The transpeptidase system which crosslinks fibrin by gamma-glutamyle-episilon-lysine bonds. Biochem Biophys Res Commun. 1968 Apr 19;31(2):222–230. doi: 10.1016/0006-291x(68)90734-1. [DOI] [PubMed] [Google Scholar]
  17. Matacić S., Loewy A. G. The identification of isopeptide crosslinks in insoluble fibrin. Biochem Biophys Res Commun. 1968 Feb 26;30(4):356–362. doi: 10.1016/0006-291x(68)90750-x. [DOI] [PubMed] [Google Scholar]
  18. ORNSTEIN L. DISC ELECTROPHORESIS. I. BACKGROUND AND THEORY. Ann N Y Acad Sci. 1964 Dec 28;121:321–349. doi: 10.1111/j.1749-6632.1964.tb14207.x. [DOI] [PubMed] [Google Scholar]
  19. Pisano J. J., Finlayson J. S., Peyton M. P. [Cross-link in fibrin polymerized by factor 13: epsilon-(gamma-glutamyl)lysine]. Science. 1968 May 24;160(3830):892–893. doi: 10.1126/science.160.3830.892. [DOI] [PubMed] [Google Scholar]
  20. SWIGERT S., KOPPEL J. L., OLWIN J. H. Selective inactivation of fibrin stabilizing factor contaminant in fibrinogen. Nature. 1963 May 25;198:797–798. doi: 10.1038/198797a0. [DOI] [PubMed] [Google Scholar]
  21. Straughn W., 3rd, Wagner R. H. A simple method for preparing fibrinogen. Thromb Diath Haemorrh. 1966 Jul 31;16(1):198–206. [PubMed] [Google Scholar]
  22. VON KAULLA K. N., SCHULTZ R. L. Methods for the evaluation of human fibrinolysis; studies with two combined technics. Am J Clin Pathol. 1958 Feb;29(2):104–112. doi: 10.1093/ajcp/29.2.104. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES